ASCO 2026 Preview: Key Data and Trends in Cancer Research

Key Takeaways

• HARMONi-6 (n=532) reported stratified OS HR 0.66 for ivonescimab plus chemo versus tislelizumab plus chemo; median OS 27.89 vs 23.69 months at 21.4 months median follow-up.
• Ivonescimab is a PD-1/VEGF bispecific (not PD-1/CTLA-4); Summit holds a U.S. BLA for a separate HARMONi EGFR-mutated NSCLC indication with PDUFA November 14, 2026.
• Revolution Medicines’ daraxonrasib (RMC-6236) Phase 3 RASolute 302 (NCT06625320) enrolled about 500 patients with previously treated metastatic PDAC.
• China-only HARMONi-6 OS does not by itself prove global benefit; U.S. practice change still hinges on multi-region confirmatory programs.

What did ivonescimab show in HARMONi-6 at ASCO 2026?

HARMONi-6 compared ivonescimab plus platinum chemotherapy with tislelizumab plus platinum chemotherapy in previously untreated advanced squamous NSCLC, regardless of PD-L1 status. At the planned interim OS analysis presented in the ASCO 2026 Plenary, the stratified hazard ratio was 0.66 (95% CI 0.50–0.87; p=0.0017).

Median OS was 27.89 months with ivonescimab plus chemo versus 23.69 months with tislelizumab plus chemo. Twenty-four-month OS rates were 64.7% versus 48.6%. Summit’s partner Akeso ran the single-region China study; results were detailed in a May 31, 2026 Business Wire release.

How does the ivonescimab mechanism differ from older checkpoint pairs?

Ivonescimab combines PD-1 blockade with VEGF inhibition in one bispecific antibody. That is distinct from classic PD-1 plus CTLA-4 combinations. Earlier HARMONi-6 progression-free survival data (PFS HR 0.60 at ESMO 2025) already supported the regimen’s activity; the 2026 OS interim answered whether PFS gains translated into longer survival in this China Phase III setting.

Investors should also track Summit’s separate global HARMONi program in EGFR-mutated non-squamous NSCLC after third-generation EGFR TKI therapy. FDA accepted a BLA in January 2026 with a PDUFA goal date of November 14, 2026, as summarized in Summit’s Q1 2026 Business Wire update.

What did Revolution Medicines present on daraxonrasib?

Daraxonrasib (RMC-6236) is an oral RAS(ON) multiselective inhibitor aimed at mutant and wild-type RAS in the GTP-bound state. Pancreatic ductal adenocarcinoma carries activating RAS mutations in more than 90% of tumors, which is why second-line metastatic PDAC data drew heavy ASCO attention.

• Phase 3 RASolute 302: NCT06625320 — ~500 patients, previously treated metastatic PDAC, daraxonrasib versus investigator-choice chemo.
• Earlier dose-finding work: NCT05379985 (RMC-6236-001) in RAS-mutant solid tumors.
• ASCO late-breaking abstract LBA5 covered primary and final RASolute 302 analyses in metastatic PDAC.

Why do China-only OS wins still leave open questions?

HARMONi-6 enrolled 532 patients in China only. Squamous NSCLC epidemiology, smoking patterns, and concurrent care differ across regions. Global confirmatory trials remain the bar for U.S. and EU label expansion of ivonescimab in first-line squamous disease.

For daraxonrasib, RASolute 302 is global, but regulators will weigh overall survival, progression-free survival by blinded review, subgroup consistency in RAS G12 versus broader RAS populations, and grade ≥3 treatment-related adverse events versus chemo. Abstract-level claims of a new second-line standard of care still require full peer-reviewed tables and label negotiations.

How should BD and competitive intelligence teams use these readouts?

For immuno-oncology portfolios, HARMONi-6 raises the bar for PD-1/VEGF bispecifics versus PD-1 plus chemo in squamous NSCLC—but only after multi-region replication. For RAS-targeted platforms, RASolute 302 is a direct comparator for any second-line PDAC asset and for partnership talks around RAS(ON) chemistry.

Cross-check protocol details and endpoints on ClinicalTrials.gov before modeling peak sales. Pair plenary slides with registry entries rather than secondary press summaries. Related pipeline context sits on our ivonescimab HARMONi-6 coverage and daraxonrasib analysis.

What remains unproven after ASCO 2026?

HARMONi-6 does not prove that ivonescimab plus chemo beats pembrolizumab plus chemo in a global population; the control arm was tislelizumab. Summit’s November 14, 2026 PDUFA decision covers a different EGFR-mutated setting, not first-line squamous NSCLC. Daraxonrasib’s full safety–efficacy trade-offs versus chemo need the complete NEJM/ASCO dataset, not only late-breaking headlines.

Related NovaPharma coverage

• Ivonescimab HARMONi-6 Lung Cancer Survival
• Revolution Medicines' Daraxonrasib: Pancreatic Cancer Breakthrough and Beyond
• Johnson And Johnson ASCO 2026 Data Adds Depth To JNJ Valuation Story

Frequently Asked Questions

Primary Sources

1. Summit / Business Wire: HARMONi-6 OS at ASCO 2026
2. ClinicalTrials.gov NCT06625320 — RASolute 302 daraxonrasib
3. ClinicalTrials.gov NCT05379985 — RMC-6236-001
4. Summit Q1 2026 Business Wire (PDUFA Nov 14, 2026)